Solid Biosciences
Advance the development of its novel gene therapy platform.
Launch date
Employees
Market cap
CAD406m
Enterprise valuation
CAD181m (Public information from Sep 2024)
Share price
$8 SLDB
Boston Massachusetts (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | 13.6m | 8.1m | - | 3.6m | <1m | 3.1m |
| % growth | - | - | (41 %) | - | - | (90 %) | 749 % |
| EBITDA | (80.6m) | (69.3m) | (108m) | (102m) | (98.6m) | (119m) | (83.9m) |
| % EBITDA margin | - | (509 %) | (1333 %) | - | (2721 %) | (32135 %) | (2672 %) |
| Profit | (88.3m) | (72.2m) | (86.0m) | (96.0m) | (106m) | (126m) | (157m) |
| % profit margin | - | (530 %) | (1062 %) | - | (2921 %) | (34108 %) | (4994 %) |
| EV / revenue | - | 5.4x | -13.4x | - | 56.9x | 593.5x | 77.5x |
| EV / EBITDA | -4.3x | -1.1x | 1.0x | - | -2.1x | -1.9x | -2.9x |
| R&D budget | 64.9m | 58.7m | 78.4m | 76.6m | - | - | - |
| R&D % of revenue | - | 431 % | 969 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | Seed | |
$42.5m | Series B | ||
$50.0m | Series C | ||
| N/A | N/A | IPO | |
* | $60.0m | Private Placement VC | |
$40.0m | Post IPO Equity | ||
* | N/A | $144m | Post IPO Equity |
* | $75.0m | Post IPO Equity | |
* | $109m | Private Placement VC | |
| Total Funding | CAD356m | ||
Related Content
Recent News about Solid Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Solid Biosciences
Edit
ACQUISITION by Solid Biosciences Sep 2022